medesispharma.com rapport :   Visitez le site

Données techniques du medesispharma.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte medesispharma.com.Actuellement, hébergé dans France et son fournisseur de services est NUXIT s.a.r.l. .

the related websites

domaine	Titre
medesispharma.com	medesis pharma » the disruptive drug delivery technology pharmaceutical company
pharma5.ma	pharma 5 - la qualité du soin commence par l'accès aux soins pour tous | pharma
disruptiveleading.com	disruptive leadership |
firstwordpharma.com	pharma industry news and analysis - firstword pharma
harmonium-pharma.fr	harmonium pharma - radicati nel diabeteharmonium pharma
onopia.com	onopia - driving growth through disruptive strategy
itnight.fr	disrupt'night la nuit de l'entreprise disruptive
geistlich.fr	geistlich - pharma - france pharma
searchlightpharma.com	searchlight pharma – searchlight pharma is a canadian-based specialty healthcare
merz.ch	home - merz pharma schweiz - merz pharma schweiz
ajcpharma.fr	ajc pharma
doc-pharma.fr	doc' pharma
mc2-pharma.fr	mc2 pharma
alliance-pharma.net	alliance pharma
pharmagoedert.com	pharma goedert s.a.

biomeridies.com pharma68.fr pharmanco.com lca-pharma.com laboratoires-thea.com gp29.net parapharmacie-pas-chere.com revue-textimage.com 

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

home corporate medesis pharma history an atypical company financing corporate team vision international scientific advisory board technology summary of technology advantages multiple drug applications of technology intellectual property products drug to treat neurodegenerative diseases alzheimer’s disease huntington’s disease drugs for the protection of populations exposed to a nuclear accident plutonium decorporation cesium decorporation nuclear radioprotection drug drug to treat type 2 diabetes aonys® drug delivery technology pipeline research personalized treatment of cancers protection of healthy tissues in cancer radiotherapy treatment of huntington’s disease publications news investors an atypical company financing become shareholders shareholder club contact us home corporate medesis pharma history an atypical company financing corporate team vision international scientific advisory board technology summary of technology advantages multiple drug applications of technology intellectual property products drug to treat neurodegenerative diseases alzheimer’s disease huntington’s disease drugs for the protection of populations exposed to a nuclear accident plutonium decorporation cesium decorporation nuclear radioprotection drug drug to treat type 2 diabetes aonys® drug delivery technology pipeline research personalized treatment of cancers protection of healthy tissues in cancer radiotherapy treatment of huntington’s disease publications news investors an atypical company financing become shareholders shareholder club contact us facebook linkedin we develop new drugs to preserve life medesis is a clinical development stage biopharmaceutical company that is engaged in the development of orally administered molecule drug candidates to address major unmet medical needs. learn more breakthrough technology to optimize drug administration aonys® allows the administration of low doses of water-soluble pharmaceutical active ingredients. the final product is deposited on the mucosa of the mouth and delivered directly into learn more preserving the brain in neurodegenerative diseases np03 is a disease-modifying nano dose formulation of lithium citrate in an aonys® reverse microemulsion. np03 allows the delivery of lithium citrate to all tissues with a strong therapeutic learn more improve the lives of patients suffering from alzheimer preclinical studies on the disease-modifying effect of np03 in ad have been conducted in mcgill university, montreal ca. np03 is a disease modifying drug and induced neurogenesis. a learn more drugs for populations contaminated during a nuclear accident after a civil or military nuclear accident, there are no suitable decorporation treatments for large contaminated populations and no approved drug to be used after irradiation and free learn more drug for children to eliminate cesium after a nuclear accident directly linked to 137cs are numerous diseases not only limited to the increased prevalence of cancers, increases in premature births and birth malformations have been observed over learn more cesium decorporation directly linked to 137cs are numerous diseases not only limited to the increased prevalence of cancers (e.g. neurological diseases). increases in premature births learn more nuclear radioprotection drug the objective of the radioprotection program is to develop a radiomitigation drug, administered in the minutes / hours following an overexposure to ionizing radiation. learn more alzheimer’s disease alzheimer’s disease is the most frequent cause of dementia and one of the most disabling conditions in the aged population. this disease, which concerns nearly learn more medesis pharma medesis is a clinical development stage biopharmaceutical company that is engaged through its unique and proven drug delivery technology – aonys ® – in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address major unmet medical needs. medesis disruptive new therapies are developed towards diseases with high unmet medical needs such as alzheimer’s and huntington’s diseases or type 2 diabetes. another strategic focus involves the development of three medical countermeasures for the protection of populations after a civil or military nuclear accident. early research programs are focused on oncology, dealing with multi-drug resistant cancers and the protection of healthy tissues during and after radiotherapy. hippocrate products & technology cesium decorporation nu02 cesium decorporation 137cs is gamma and beta emitting by-product of uranium fission. large quantities of 137cs were released into the atmosphere during the chernobyl and fukushima disasters. 137cs is water soluble and therefore can travel large distances from the site of release and enter into the food chain with learn more aonys® drug delivery technology aonys® is a mix of lipidic components that spontaneously assemble into a water-in-oil microemulsion. the active agent is solubilized in the aqueous phase of the microemulsion, within reverse micelles of 4 to 5 nm in diameter. aonys® allows the administration of low doses of water-soluble pharmaceutical active ingredients. learn more drug to treat neurodegenerative diseases np03 is a disease-modifying nano dose formulation of lithium citrate in an aonys® reverse microemulsion. np03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at doses two orders of magnitude lower than those used in currently marketed lithium specialties. studies on transgenic animal learn more pipeline guidelines for classical drug development, guidelines “animal rules” and research programs learn more medesis pharma © 2018 / the disruptive drug delivery technology pharmaceutical company contact us

Analyse PopURL pour medesispharma.com

http://www.medesispharma.com/category/products/
http://www.medesispharma.com/products/nuclear-decorporation-drugs/
http://www.medesispharma.com/corporate/an-atypical-company-financing/
http://www.medesispharma.com/category/investors/
http://www.medesispharma.com/fr/
http://www.medesispharma.com/category/research/
http://www.medesispharma.com/research/oncology-personalized-treatment-of-cancers/
http://www.medesispharma.com/technology/intellectual-property/
http://www.medesispharma.com/products/drug-to-treat-type-2-diabetes/
http://www.medesispharma.com/products/nuclear-radioprotection-drug/
http://www.medesispharma.com/products/huntingtons-disease/
http://www.medesispharma.com/corporate/corporate-team/
http://www.medesispharma.com/corporate/scientific-publications/
http://www.medesispharma.com/corporate/vision/
http://www.medesispharma.com/investors/become-shareholders/

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: MEDESISPHARMA.COM
Registry Domain ID: 125218668_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corehub.net
Registrar URL: http://corehub.net
Updated Date: 2017-06-21T14:26:03Z
Creation Date: 2004-07-20T12:31:38Z
Registry Expiry Date: 2018-07-20T12:31:38Z
Registrar: Corehub, S.R.L.
Registrar IANA ID: 15
Registrar Abuse Contact Email: abuse@corehub.net
Registrar Abuse Contact Phone: +34935275235
Domain Status: ok https://icann.org/epp#ok
Name Server: DNS2.FRENCH-CONNEXION.COM
Name Server: DNS5.FRENCH-CONNEXION.COM
Name Server: DNS50.DOMAINE.FR
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-18T23:46:29Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Corehub, S.R.L.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =medesispharma.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME medesispharma.com

  CHANGED 2017-06-21

  CREATED 2004-07-20

STATUS
ok https://icann.org/epp#ok

NSERVER

  DNS2.FRENCH-CONNEXION.COM 216.15.153.90

  DNS5.FRENCH-CONNEXION.COM 64.77.49.164

  DNS50.DOMAINE.FR 159.100.131.27

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.